Talha Nawaz, MD
Pulmonary Disease · Montgomery, OHNPI 1639585094
Payments from drug & device makers
Across 240 payments — averaging $41.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$1K
- Johnson & Johnson$1K
- Pulmonx Corporation$1K
- Boehringer Ingelheim$389
- Actelion Pharmaceuticals US, Inc.$336
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2,31023%
- Food & beverage$4,37244%
- Education$3,19932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $3,512 |
| GSK | 114 | $1,495 |
| Johnson & Johnson(2 entities) | 9 | $1,311 |
| Pulmonx Corporation | 5 | $1,027 |
| Boehringer Ingelheim | 16 | $389 |
| Actelion Pharmaceuticals US, Inc. | 10 | $336 |
| AstraZeneca(2 entities) | 13 | $228 |
| Sanofi | 9 | $192 |
| Insmed, Inc. | 4 | $171 |
| Steris Corporation | 1 | $117 |
| Merck | 5 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Electromed, Inc. | 14 | $93 |
| Covidien LP | 1 | $93 |
| Mallinckrodt Hospital Products Inc. | 5 | $92 |
| Abiomed | 1 | $73 |
| Astellas Pharma US Inc | 3 | $66 |
| Grifols USA, LLC | 3 | $56 |
| Mylan Specialty L.p. | 3 | $50 |
| United Therapeutics Corporation | 2 | $48 |
| Bayer | 2 | $33 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| AbbVie | 1 | $26 |
| Inogen, Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Sandoz | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Monarch Platform$1,165
- ZEPHYR ENDOBRONCHIAL VALVE$1,020
- Da Vinci Surgical System$400
- OFEV$121
- TRUFREEZE$117
- Arikayce$105
How this compares
$9,882 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 316 | $274,520 |
| OfevNintedanib Esylate | 15 | $195,494 |
| NucalaMepolizumab | 20 | $72,008 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $41,033 |
| Spiriva RespimatTiotropium Bromide | 50 | $37,307 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $33,027 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $32,103 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $13,805 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 332 | $11,364 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,059 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $8,334 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,562 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $5,216 |
| DuleraMometasone/Formoterol | 11 | $3,476 |
| Tiotropium Bromide | 11 | $2,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,495 | $403,182451 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $389 | $246,60693 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $228 | $65,129150 claims |
| MerckDulera | $117 | $3,47611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Montgomery
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.